4% growth forecast for generic drugs market in Central Europe between 2012 and 2014
According to Polish market research firm PMR’s report, titled generic and innovative drugs market in Central Europe 2012, the generic drug market in the region will increase by 2% year on year in 2012, to 6.8 billion euros ($8.63 billion) at manufacturer selling prices.
In 2012 the market growth rate will be slightly lower than that of 2011 and will fluctuate around 2%. In general, between 2012 and 2014 the market will develop at a compound annual growth rate (CAGR) of 4%, ie, faster than the innovative drug market, which will increase by 2% per annum on average, according to PMR’s forecasts.
Most of the pharmaceutical markets of the Central European countries are dominated by generic medicines. The share of generics as a proportion of the pharmacy market in terms of value is at its highest in Poland and at its lowest in Romania, among the CE countries. In Bulgaria and the Czech Republic, generic drugs account for around half of the market by value.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze